Screener
Spyre Therapeutics, Inc. SYRE Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(69,005) | $(44,773) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 12,806 | 8,859 |
| Acquired in-process research and development | — | — |
| Change in fair value of CVR liability | 30,270 | (2,400) |
| Gain on sale of in-process research and development asset | (30,000) | — |
| Net accretion of discount on marketable securities | (2,059) | (2,642) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s stock-based comp?
- Spyre Therapeutics, Inc. (SYRE) reported stock-based comp of $12.81M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Spyre Therapeutics, Inc.'s stock-based comp increased by 44.6% year-over-year, from $8.86M to $12.81M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s stock-based comp has grown at a 47.1% compound annual growth rate (CAGR), from $8.04M to $37.61M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Spyre Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude